Terms: = Prostate cancer AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1 AND Prognosis
13 results:
1. A first-in-class HBO1 inhibitor WM-3835 inhibits castration-resistant prostate cancer cell growth in vitro and in vivo.
Mi YY; Ji Y; Zhang L; Sun CY; Wei BB; Yang DJ; Wan HY; Qi XW; Wu S; Zhu LJ
Cell Death Dis; 2023 Jan; 14(1):67. PubMed ID: 36709328
[TBL] [Abstract] [Full Text] [Related]
2. Expression of phosphatase of regenerating liver (PRL)-3, is independently associated with biochemical failure, clinical failure and death in prostate cancer.
Andersen S; Richardsen E; Rakaee M; Bertilsson H; Bremnes R; Børset M; Busund LT; Slørdahl T
PLoS One; 2017; 12(11):e0189000. PubMed ID: 29190795
[TBL] [Abstract] [Full Text] [Related]
3. Genetic interaction of P2X7 receptor and vegfr-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients.
Solini A; Simeon V; Derosa L; Orlandi P; Rossi C; Fontana A; Galli L; Di Desidero T; Fioravanti A; Lucchesi S; Coltelli L; Ginocchi L; Allegrini G; Danesi R; Falcone A; Bocci G
Oncotarget; 2015 Oct; 6(30):28743-54. PubMed ID: 26337470
[TBL] [Abstract] [Full Text] [Related]
4. vegfr-1 overexpression identifies a small subgroup of aggressive prostate cancers in patients treated by prostatectomy.
Tsourlakis MC; Khosrawi P; Weigand P; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Krech T; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S
Int J Mol Sci; 2015 Apr; 16(4):8591-606. PubMed ID: 25894226
[TBL] [Abstract] [Full Text] [Related]
5. Associations of nm23H1, VEGF-C, and VEGF-3 receptor in human prostate cancer.
Yang ZS; Xu YF; Huang FF; Ding GF
Molecules; 2014 May; 19(5):6851-62. PubMed ID: 24858271
[TBL] [Abstract] [Full Text] [Related]
6. Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer.
Brooks C; Sheu T; Bridges K; Mason K; Kuban D; Mathew P; Meyn R
Radiat Oncol; 2012 Sep; 7():154. PubMed ID: 22967802
[TBL] [Abstract] [Full Text] [Related]
7. Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients.
Castellano D; González-Larriba JL; Antón-Aparicio LM; Cassinello J; Grande E; Esteban E; Sepúlveda J
Expert Opin Pharmacother; 2011 Nov; 12(16):2433-9. PubMed ID: 21671835
[TBL] [Abstract] [Full Text] [Related]
8. Interaction among variant vascular endothelial growth factor (VEGF) and its receptor in relation to prostate cancer risk.
VanCleave TT; Moore JH; Benford ML; Brock GN; Kalbfleisch T; Baumgartner RN; Lillard JW; Kittles RA; Kidd LC
Prostate; 2010 Mar; 70(4):341-52. PubMed ID: 19908237
[TBL] [Abstract] [Full Text] [Related]
9. CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients.
Salnikov AV; Gladkich J; Moldenhauer G; Volm M; Mattern J; Herr I
Int J Cancer; 2010 Feb; 126(4):950-8. PubMed ID: 19676044
[TBL] [Abstract] [Full Text] [Related]
10. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D
Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197
[TBL] [Abstract] [Full Text] [Related]
11. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract] [Full Text] [Related]
12. Increased expression of VEGF-receptors (FLT-1, kdr, NRP-1) and thrombospondin-1 is associated with glomeruloid microvascular proliferation, an aggressive angiogenic phenotype, in malignant melanoma.
Straume O; Akslen LA
Angiogenesis; 2003; 6(4):295-301. PubMed ID: 15166498
[TBL] [Abstract] [Full Text] [Related]
13. Molecular pathway for cancer metastasis to bone.
De S; Chen J; Narizhneva NV; Heston W; Brainard J; Sage EH; Byzova TV
J Biol Chem; 2003 Oct; 278(40):39044-50. PubMed ID: 12885781
[TBL] [Abstract] [Full Text] [Related]
